You selected: Hepatology
NASH-Induced Cirrhosis Rivals HCV in Development of Hepatocellular Carcinoma
Presence and Type of Complications Predictors of Mortality
Modifying Risk Factors Essential in Controlling Liver Disease Progression
Urban HCV Patients Adversely Affected by Social Factors In the Health Care Environment
Sirolimus-Based Immunosuppression and Radiofrequency Ablation are Promising Treatments for HCC
Short-Term Therapy with Oral Losartan Not Effective in Reducing Fibrosis
A recent study found that rats with advanced fibrosis that were administered a short-term dose of losartan-M6PHSA had reduced liver inflammation and fibrosis. Those animals treated with oral losartan alone did not experience a similar reduction in disease activity. Results of this study appear in the March issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Study Suggests Stomach Hormone May Offer Novel Fibrosis Therapy
Spanish researchers determined that rats treated with recombinant ghrelin displayed a reduction in liver fibrosis. Ghrelin, a stomach hormone, reduced the amount of fibrogenic cells by 25% in the treated rodents. Research further showed ghrelin prevented acute liver damage and reduced oxidative stress and inflammation in the animal models. Details of this study are published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.
Institute of Medicine Makes Recommendations to Prevent HBV and HCV Infections
Study Confirms Accuracy of Transient Elastography in NAFLD Sonic Detection of Liver Stiffness Emerges as a Useful Screening and Prognostic Test
Researchers from France and Hong Kong determined that transient elastography (TE), a noninvasive, ultrasonic imaging modality, can be accurately performed in the majority of patients with nonalcoholic fatty liver disease (NAFLD) to exclude advanced fibrosis. Full findings of this study, funded by the Chinese University of Hong Kong, appear in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Researchers from the Karolinska Institute determined that patients with nonalcoholic fatty liver disease (NAFLD) have a higher overall mortality rate compared with the general population. Details of this study are available in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Study Finds Caffeine in Sources other than Coffee Does Not Have Similar Effect
Life-Saving Therapeutic Interventions Possible with Early Detection of Hepatitis C Recurrence
Impaired Oxidation in Liver Associated with Progression to NASH
Research Suggests Lack of Diagnosis is Primary Barrier to Treatment
Patients with Positive Epithelial-Mesenchymal Transition Markers Have Lowest Survival Rate
Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers.
Up to 80% of Cirrhotic Patients Develop Difficulties with Cognitive Function
Benefits Are Not Dependent On Weight Loss - Research News from Hepatology
Study Finds Adverse Effects in Treatment for Primary Sclerosing Cholangitis: High-Dose Ursodeoxycholic Acid Associated with Worsened Disease State for Patients with PSC
Research News from Hepatology